*** Welcome to piglix ***

Biogen Idec

Biogen
Public
Traded as
Industry Biotechnology
Founded 1978 (from merger)
Founders Kenneth Murray
Phillip Allen Sharp
Walter Gilbert
Charles Weissmann
Headquarters Cambridge, Massachusetts, U.S.
Key people
Stelios Papadopoulos, Chairman
George A. Scangos, CEO
Products Alprolix, Avonex, Eloctate, Fampyra, Gazyva*, Plegridy, Rituxan*, Tecfidera, Tysabri
Revenue IncreaseUS$ 10.76 billion (2015) <
IncreaseUS$ 4.89 billion (2015)
Increase US$ 3.55 billion (2015)
Total assets Increase US$ 19.505 billion (2015)
Total equity Decrease US$ 9.37 billion (2014)
Number of employees
7,350 (December 2015)
Website www.biogen.com

Biogen, Inc. (previously known as Biogen Idec) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

Biogen was founded in 1978 in Geneva by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase), Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich (who contributed the first product interferon alpha). Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.


...
Wikipedia

...